Ectin Research AB

Our novel cancer therapy MFA-370 developed following the remarkable, unexpected remission of a terminal bladder cancer patient. Ectin: Medicine not ‘miracle’

[Ectin Research AB @EctinAb]

Det har varit ett viktigt och uppmuntrande kvartal för Ectin Research! Läs hela Q3 rapporten här! https://t.co/WDSNxVIM9H #cancerbehandling

[Ectin Research AB @EctinAb]

Exciting news in metastatic cancer treatment! MFA-370 has shown a unique effect on genes that regulate tumour cell growth in new preclinical data from a gene expression analysis of 3 different cancer cell models! https://t.co/mrZUIefwsu #tcancer

[Ectin Research AB @EctinAb]

Viktiga nyheter! Nya prekliniska data från genexpressionsanalys av tre olika cancercellsmodeller visar hur vår kombinationbehandling MFA-370 har unik och omfattande effekt på gener som reglerar tumörcellers tillväxt. Läs hela pressmeddelandet här: https://t.co/9SDGpl1tgU #FiTwi

[Ectin Research AB @EctinAb]

Vår årsredovisning för 2023 har nu släppts! VD Anna Sjöblom-Hallén: ”2023 har varit ett spännande år med vår kombinationsbehandling MFA-370 för behandling av cancer. MFA-370 är en oral behandling med endast milda potentiella biverkningar" https://t.co/ziVrembot4 #FiTwi

[Ectin Research AB @EctinAb]

Uvealt melanom är en ovanlig form av malignt melanom som drabbar ögat. I en intervju med BioStock pratar vd Anna Sjöblom-Hallén om hur bolaget utvecklat nya zebrafiskmodeller för att studera hur MFA370 påverkar tumörutvecklingen för UM. https://t.co/ULkWmYbqap #CancerResearch

[Ectin Research AB @EctinAb]

Uveal melanoma is a rare a form of malignant melanoma that affects the eye. We have now created and validated translatable model systems for UM in zebrafish & in 2024 we hope to be able to demonstrate positive data. Learn more here: https://t.co/eZqia7Xb7t

[Ectin Research AB @EctinAb]

#RareDiseasesDay raises awareness of 7000 diseases affecting 300 million people. One is #UvealMelanoma, an aggressive eye cancer. MFA-370 has shown potential to treat UM in preclinical tumour models, we hope to take it forward. Donate to Rare Diseases Day https://t.co/neOpcTDPrs

[Ectin Research AB @EctinAb]

Ectin has reported strong preclinical development of MFA-370 with new positive animal data on triple negative breast cancer tumors. Read the Q4 report here https://t.co/DQ6wMEzBj9 #breastcancer

[Ectin Research AB @EctinAb]

Great to see our CEO Anna Sjöblom-Hallén adding her expertise and experience to the impressive panel at the 'Roadmap for an IPO - A Guide to Going Public' event at #GoWest 2024!

[Ectin Research AB @EctinAb]

Ectin Research CEO Anna Sjöblom-Hallén has been chosen for an expert panel discussion at #GoWest2024 ‘Roadmap for an IPO - A Guide to Going Public’. Join her and the panel as they share their experiences and insights! https://t.co/TqMtS3vqUC

[Ectin Research AB @EctinAb]

We are pleased to share that preclinical studies of our combination therapy MFA-370 indicate both a growth-dampening & tumor-shrinking effect on triple-negative breast cancer tumors in an animal model. https://t.co/H9pZ25W3Xa #bladdercancer #colorectalcancer #prostatecancer

[Ectin Research AB @EctinAb]

We believe MFA-370 will be a new safer treatment option for metastatic cancer tumours significantly improving the quality of life for late-stage #Cancer patients. Book a meeting with Ectin Research CEO Anna Sjöblom-Hallen at #GoWest2024 https://t.co/TqMtS3vqUC #FinTwitt

[Ectin Research AB @EctinAb]

Meet Ectin Research CEO Anna Sjöblom-Hallen at #GoWest2024 to discuss MFA-370, a novel therapy for inhibiting the growth of metastatic cancer tumours with few if any side effects. https://t.co/TqMtS3vqUC #FiTwi #investors

[Ectin Research AB @EctinAb]

Vårt fokus under 2023 har varit en satsning på preklinisk verksamhet och det här har givit viktiga positiva resultat med nya data för behandling av trippelnegativ bröstcancer (TNBC) och uvealt melanom (UM). Läs Q3 rapport här! https://t.co/xuB821KOmk #finanstwitter

[Ectin Research AB @EctinAb]

"We're having some really interesting, productive meetings, it's a great event!" Meet Ectin Research's CEO Anna Sjöblom-Hallen at #BIOEurope to discuss a novel, repurposed combination therapy for eliminating cancer tumours with few side effects - MFA-370 https://t.co/mHldx1vMJy

[Ectin Research AB @EctinAb]

Meet Ectin Research CEO Anna Sjöblom-Hallén at #BIOEurope to hear about MFA-370, our repurposed combination therapy to treat metastatic urothelial bladder cancer & positive preclinical findings on triple negative breast cancer and uveal melanoma. https://t.co/8C9Ko73zod

[Ectin Research AB @EctinAb]

Meet CEO Anna Sjöblom-Hallén at #bioeurope2023 and get the latest data on MFA-370, our ground breaking repurposed combination therapy aiming to be an easy-to-administer oral tablet to eradicate cancer tumors. https://t.co/OhtklCvl1b #finanstwitter

[Ectin Research AB @EctinAb]

New preclinical studies strengthen our previous results & show promising results that our therapy MFA-370 could be used to treat additional cancer indications including triple negative breast cancer & uveal melanoma https://t.co/iQF0cQN3a5 #fitwi #finanstwitter

[Ectin Research AB @EctinAb]

"Repurposing previously tried and tested drugs is exciting. An oral formulation for end-stage oncology patients will simplify dosage regime and add a huge convenience factor to the patient" meet Ectin Research's DTO Kevan Cassidy https://t.co/sHuKhaFvDo #finansx #oncology

[Ectin Research AB @EctinAb]

Meet our CEO Anna Sjöblom-Hallén at #BIOEuropeSpring March 20-22 & explore MFA-370, our therapy for metastatic urothelial bladder cancer, and potentially other tumours that is planned to be a simple oral tablet with few if any side effects. https://t.co/8C9Ko73zod #finanstwitter